Biomedical prevention interventions have helped prevent new HIV acquisitions and are saving lives. However, the decline in HIV incidence has been far from meeting the 90-90-90 UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity to achieve durable control and an end to the HIV epidemic. To develop such a vaccine, a renewed contribution from and participation by the pharmaceutical industry is necessary. The unprecedented success of research and development (R&D) for COVID-19 vaccines has shown that the pharmaceutical industry, in partnership with public research institutions, can deliver on a global public health challenge in record time. As the field of vaccinology moves beyond the acute response to the COVID-19 pandemic, there is an immediate need to recover momentum in HIV vaccine R&D by ensuring that it has the maximum interest, engagement and investment from the biopharmaceutical industry. This satellite will discuss barriers to industry involvement in HIV vaccine R&D, including recommendations for activating and optimizing industry participation in R&D. The event will also be an opportunity to launch the IAS Global HIV Vaccine Enterprise Industry Partnership, a multi-stakeholder group aiming to support industry's contribution to HIV vaccine R&D by addressing and minimizing barriers to engagement.

• Presentations
• Session recording (English)